Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.

Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.
Dialogues Clin Neurosci. 2016 Sep;18(3):323-337
Authors: Eum S, Lee AM, Bishop JR
Abstract
Optimizing antipsychotic pharmacotherapy is often challenging due to significant variability in effectiveness and tolerability. Genetic factors influencing pharmacokinetics and pharmacodynamics may contribute to some of this variability. Research studies have characterized these pharmacogenetic relationships, and some genetic markers are now available as clinical tests. These advances in pharmacogenetics research and test availability have great potential to improve clinical outcomes and quality of life in psychiatric patients. For clinicians considering using pharmacogenetics, it is important to understand the clinical implications and also the limitations of markers included in currently available tests. This review focuses on pharmacokinetic and pharmacodynamic gene variants that are currently available in commercial genetic testing panels. Associations of these variants with clinical efficacy and adverse effects, as well as other clinical implications, in antipsychotic pharmacotherapy are discussed.
PMID: 27757066 [PubMed - in process]

Source: Dialogues in Clinical Neuroscience - October 22, 2016 Category: Neuroscience Tags: Dialogues Clin Neurosci Source Type: research